文献速递临床试验与 GCP

神术冠心方颗粒治疗冠心病患者疗效与安全性的双盲随机对照试验方案

The efficacy and safety of Shenzhu Guanxin Recipe Granules for the treatment of patients with coronary artery disease: protocol for a double-blind, randomized controlled trial.
PubMed 文献 · Trials · 2019-08-20

这是一项双盲随机对照试验方案,计划纳入190例经冠脉CT血管成像显示50-70%狭窄且为软斑块或混合斑块的冠心病患者,按1:1随机分为神术冠心方颗粒联合常规治疗组与安慰剂联合常规治疗组,安慰剂6克/天用6个月,评估钙覆盖评分、炎症指标、血脂及西雅图心绞痛量表等。

要点

  • 纳入经临床表现和检查诊断、冠脉CT血管成像示50-70%狭窄且为软斑块或混合斑块的冠心病患者190例。
  • 按1:1随机分为神术冠心方颗粒联合常规治疗组与安慰剂(6克/天,6个月)联合常规治疗组。
  • 终点包括钙覆盖评分、C反应蛋白、血脂、肿瘤坏死因子-α、白介素-1、白介素-6、ATP结合膜盒转运蛋白A1及西雅图心绞痛量表与中医证候问卷评分。

核心结论

  • 该临床试验可能为神术冠心方颗粒治疗经临床表现和检查诊断、冠脉CT血管成像示50-70%狭窄且为软斑块或混合斑块的冠心病患者提供临床有效性和安全性的可靠证据。

研究设计与样本

  • 双盲随机对照试验方案,招募190例经临床表现和检查诊断、冠脉CT血管成像示50-70%狭窄且为软斑块或混合斑块的冠心病患者。
  • 采用1:1分配比例随机分为病例组和对照组,病例组接受神术冠心方颗粒联合常规治疗,对照组接受安慰剂(6克/天,用6个月)联合常规治疗。

主要发现

  • 研究终点包括钙覆盖评分、C反应蛋白水平及血脂、肿瘤坏死因子-α、白介素-1、白介素-6、ATP结合膜盒转运蛋白A1水平,在招募前和第6个月计算。
  • 观察指标为第0、3、6个月的西雅图心绞痛量表和中医证候问卷评分。

关键数值与推荐

  • 纳入标准为经临床表现和检查诊断的冠心病,冠脉CT血管成像显示50-70%狭窄,斑块类型为软斑块或混合斑块。
  • 安慰剂剂量为6克/天,疗程6个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronary artery disease (CAD) is one of the most common types of the cardiovascular disease. Previous pilot trials have suggested that Traditional Chinese Medicine (TCM) has brought clinical benefits for patients with CAD. We will conduct this trial to determine the efficacy and safety of Shenzhu Guanxin Recipe Granules (SGR) for the treatment of patients with CAD. METHODS: This randomized controlled trial recruited 190 patients who were diagnosed with CAD by clinical manifestation and examination and in which coronary computed tomography angiography (CCTA) showed 50-70% stenosis, with soft or mixed plaque types. The included participants were randomly assigned to the case group and control group using a 1:1 allocation ratio; patients in the case group received SGR and usual care, and those in the control group received placebo (6 g/day for 6 months) and usual care. The endpoint of the study included Calcium Coverage Score (CCS), C-reactive protein (CRP) level, and the levels of blood lipids, tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and ATP-binding membrane cassette transporter A1 (ABCA1) were calculated before recruiting and at the sixth month. The indicators were Seattle Angina Questionnaire (SAQ) and TCM Syndrome Questionnaire scores at 0, 3, and 6 months. DISCUSSION: This clinical trial may provide reliable evidence regarding the clinical effectiveness and safety of SGR therapy for patients with CAD diagnosed by clinical manifestation and examination, in which CCTA showed 50-70% stenosis, with soft or mixed plaque types. TRIAL REGISTRATION: ClinicalTrials.gov, ID: ChiCTR1900020501 . The trial was registered on 25 December 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jin X, Pan B, Wu H, et al. The efficacy and safety of Shenzhu Guanxin Recipe Granules for the treatment of patients with coronary artery disease: protocol for a double-blind, randomized controlled trial. Trials. 2019. PMID: 31429810. doi:10.1186/s13063-019-3629-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。